Sonsoles Rodríguez-Arístegui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sonsoles Rodríguez-Arístegui has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Joaquín Pastor
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain
4 shared publications - Sonia Martínez
Experimental Therapeutics Programme Spanish National Cancer Research Centre (CNIO) Madrid Spain
4 shared publications - Carmen Varela
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain
3 shared publications Ian R. Hardcastle
Newcastle Cancer Centre, Northern Institute for Cancer Research, School of Chemistry, Bedson Building, Newcastle University, Newcastle upon Tyne, United Kingdom
3 shared publicationsJames R. Bischoff
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain
3 shared publications- María Isabel Albarrán
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain
3 shared publications
Latest Publications
- 1 June 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (11) , 2536-2543
Generation of tricyclic imidazo[1,2- a ]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy
- 1 June 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (11) , 2536-2543
Generation of tricyclic imidazo[1,2- a ]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy
- 29 March 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (10) , 3460-3466
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor
- 29 March 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (10) , 3460-3466
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor
- 1 March 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (5) , 1874-1878
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors
- 1 March 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (5) , 1874-1878
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors
- 1 February 2012
- Published by Elsevier in Tetrahedron Letters
- Vol. 53 (9) , 1082-1084
New use of bis(benzotriazolyl)-1,2-(dialkylamino)ethanes for the synthesis of 2-H-3-dialkylamino imidazo[1,2-a]pyrazine derivatives
- 1 February 2012
- Published by Elsevier in Tetrahedron Letters
- Vol. 53 (9) , 1082-1084
New use of bis(benzotriazolyl)-1,2-(dialkylamino)ethanes for the synthesis of 2-H-3-dialkylamino imidazo[1,2-a]pyrazine derivatives
- 18 May 2011
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 9 (17) , 6066-6074
Versatile synthesis of functionalised dibenzothiophenes via Suzuki coupling and microwave-assisted ring closure
Amino-substituted biphenyls were obtained by Suzuki cross-coupling of 2,6-dibromoaniline with a phenylboronic acid (substituted with Me, NO2, OH, OMe or Cl) preferably assisted by microwave irradiation. Conversion of the amino group into a thiol preceded a base-induced intramolecular substitution, also facilitated by microwave heating, to generate the second C–S bond of the target dibenzothiophene. The 1-, 2-, 3- or 4-substituted 6-halodibenzothiophenes obtained were subjected to a palladium-mediated coupling with 2-morpholin-4-yl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-chromen-4-one to give the respective 6-, 7-, 8- or 9-substituted dibenzothiophen-4-ylchromenones. These compounds were evaluated as inhibitors of DNA-dependent protein kinase (DNA-PK) and compared to the parent 8-(dibenzo[b,d]thiophen-4-yl)-2-morpholin-4-yl-4H-chromen-4-one. Notably, derivatives bearing hydroxy or methoxy substituents at C-8 or C-9 retained activity, whereas substitution at C-7 lowered activity. Substitution with chloro at C-6 was not detrimental to activity, but a chloro group at C-7 or C-8 reduced potency. The data indicate permissive elaboration of hydroxyl at C-8 or C-9, enabling the possibility of improved pharmaceutical properties, whilst retaining potency against DNA-PK.
- 18 May 2011
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 9 (17) , 6066-6074
Versatile synthesis of functionalised dibenzothiophenes via Suzuki coupling and microwave-assisted ring closure
Amino-substituted biphenyls were obtained by Suzuki cross-coupling of 2,6-dibromoaniline with a phenylboronic acid (substituted with Me, NO2, OH, OMe or Cl) preferably assisted by microwave irradiation. Conversion of the amino group into a thiol preceded a base-induced intramolecular substitution, also facilitated by microwave heating, to generate the second C–S bond of the target dibenzothiophene. The 1-, 2-, 3- or 4-substituted 6-halodibenzothiophenes obtained were subjected to a palladium-mediated coupling with 2-morpholin-4-yl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-chromen-4-one to give the respective 6-, 7-, 8- or 9-substituted dibenzothiophen-4-ylchromenones. These compounds were evaluated as inhibitors of DNA-dependent protein kinase (DNA-PK) and compared to the parent 8-(dibenzo[b,d]thiophen-4-yl)-2-morpholin-4-yl-4H-chromen-4-one. Notably, derivatives bearing hydroxy or methoxy substituents at C-8 or C-9 retained activity, whereas substitution at C-7 lowered activity. Substitution with chloro at C-6 was not detrimental to activity, but a chloro group at C-7 or C-8 reduced potency. The data indicate permissive elaboration of hydroxyl at C-8 or C-9, enabling the possibility of improved pharmaceutical properties, whilst retaining potency against DNA-PK.
- 1 June 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (12) , 3649-3653
Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors
- 1 June 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (12) , 3649-3653
Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors
- 18 November 2006
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 8 (26) , 5927-5929
Judicious Application of Allyl Protecting Groups for the Synthesis of 2-Morpholin-4-yl-4-oxo-4H-chromen-8-yl Triflate, a Key Precursor of DNA-Dependent Protein Kinase Inhibitors
2-Morpholin-4-yl-4-oxo-4H-chromen-8-yl 2,2,2-trifluoromethanesulfonate is a key intermediate for the synthesis of the DNA-dependent protein kinase (DNA-PK) inhibitor 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441). Two improved methods for the synthesis of this triflate have been developed: (A) in 35% overall yield, through modification of the published route, and (B) in 15% overall yield, by a new route employing a Baker−Venkataraman rearrangement to enable generation of the chromenone scaffold. Both syntheses depend on the judicious use of allyl protecting groups.
- 18 November 2006
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 8 (26) , 5927-5929
Judicious Application of Allyl Protecting Groups for the Synthesis of 2-Morpholin-4-yl-4-oxo-4H-chromen-8-yl Triflate, a Key Precursor of DNA-Dependent Protein Kinase Inhibitors
2-Morpholin-4-yl-4-oxo-4H-chromen-8-yl 2,2,2-trifluoromethanesulfonate is a key intermediate for the synthesis of the DNA-dependent protein kinase (DNA-PK) inhibitor 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441). Two improved methods for the synthesis of this triflate have been developed: (A) in 35% overall yield, through modification of the published route, and (B) in 15% overall yield, by a new route employing a Baker−Venkataraman rearrangement to enable generation of the chromenone scaffold. Both syntheses depend on the judicious use of allyl protecting groups.